PARTS iD, Inc. to Present at 2021 ICR Conference

PARTS iD, Inc. to Present at 2021 ICR Conference

CRANBURY, N.J.–(BUSINESS WIRE)–
PARTS iD, Inc. (NYSE American: ID) (“PARTS iD” or “Company), the owner and operator of, among other verticals, “CARiD.com,” a leading digital commerce platform for the automotive aftermarket, announced today that the Company will participate in the 2021 ICR Conference. Management is scheduled to present on Wednesday, January 13, 2021 at 10:30 a.m. Eastern Time. A live webcast of the presentation will be available at https://www.partsidinc.com/.

About PARTS iD, Inc.

PARTS iD is a technology-driven, digital commerce company focused on creating custom infrastructure and unique user experiences within niche markets. Founded in 2008 with a vision of creating a one-stop eCommerce destination for the automotive parts and accessories market, PARTS iD has since become a market leader and proven brand-builder, fueled by its commitment to delivering a revolutionary shopping experience; comprehensive, accurate and varied product offerings; and continued digital commerce innovation.

Dawn Francfort / Brendon Frey

ICR

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Motorcycles Aftermarket Automotive Specialty Other Automotive Online Retail General Automotive Retail

MEDIA:

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee

BRISBANE, Calif.–(BUSINESS WIRE)–
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021.

“Sung has contributed significantly to Sangamo’s evolution, helping us build a strong cash position to advance proprietary medicines for patients in need as we begin a year with several potential catalysts,” said Sandy Macrae, Chief Executive Officer of Sangamo. “I have deep appreciation for the integrity and leadership Sung brought to Sangamo. The management team and board of directors at Sangamo join me in wishing him the very best as we initiate our search for a new CFO.”

“It has been a privilege to work with Sandy and the Sangamo team to advance the innovative field of genomic medicine, and I believe the company is well positioned to execute on its strategy,” said Mr. Lee.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.

Investor Relations & Media Inquiries

Aron Feingold

628.252.7494

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health Genetics Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

Columbia Sportswear Company Appoints John Culver, Leader of International Growth at Starbucks Corp., to Its Board of Directors

Columbia Sportswear Company Appoints John Culver, Leader of International Growth at Starbucks Corp., to Its Board of Directors

PORTLAND, Ore.–(BUSINESS WIRE)–
Columbia Sportswear Company (Nasdaq: COLM), a global leader in designing, sourcing, marketing, and distributing outdoor, active and everyday lifestyle apparel, footwear, accessories, and equipment products, today announced that its board of directors appointed John Culver to serve as a director and member of its Compensation Committee, effective January 5, 2021.

Mr. Culver currently serves as Starbucks Corp. (Nasdaq: SBUX) group president of International, Channel Development and Global Coffee, Tea and Cocoa, and is a member of the Starbucks executive leadership team. He has responsibility for leading Starbucks retail growth and operations in 60 markets across China, Asia Pacific, Europe, Middle East and Africa (EMEA) and growth for the Global Channel Development business which includes Consumer Packaged Goods (CPG), Foodservice and Evolution Fresh. Mr. Culver also has the additional responsibility of leading the growth and development of Starbucks coffee, tea and cocoa businesses.

Mr. Culver serves on the board of directors and audit committee of Kimberly-Clark (NYSE: KMB) and is a director of The Mission Continues, a national, nonpartisan nonprofit that empowers veterans to continue their service, leveraging their talent and skills to generate visible impact for communities. He has a B.S. in Business Administration from Florida State University.

“We are thrilled to have John join our board of directors,” said Chairman, President and CEO, Tim Boyle. “John has been instrumental in driving international growth in various markets at Starbucks for almost twenty years and we are excited for him to bring that knowledge and expertise to our board of directors as we continue to focus on unlocking our international omni-channel growth opportunities. Mr. Culver also brings a deep understanding of the consumer and consumer trends, including the digital transformation, which we hope to leverage during his service on the Board.”

About Columbia Sportswear Company

Columbia Sportswear Company has assembled a portfolio of brands for active lives, making it a leader in the global active outdoor lifestyle apparel, footwear, accessories, and equipment industry. Founded in 1938 in Portland, Oregon, the Company’s brands are today sold in approximately 90 countries. In addition to the Columbia® brand, Columbia Sportswear Company also owns the Mountain Hardwear®, SOREL® and prAna® brands. To learn more, please visit the Company’s websites at www.columbia.com, www.mountainhardwear.com, www.sorel.com, and www.prana.com.

Andrew Burns, CFA

Director of Investor Relations and Competitive Intelligence

Columbia Sportswear Company

(503) 985-4112

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Textiles Other Sports Sports Other Retail Specialty Manufacturing Fashion Retail Outdoors Online Retail

MEDIA:

Logo
Logo

Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors

Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors

HAYWARD, Calif.–(BUSINESS WIRE)–
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely competitive drug discovery and development organizations, including in the fields of oncology and immuno-oncology.

“As we head into a pivotal year for Arcus that will include multiple randomized clinical readouts with four of our molecules, the initiation of key registrational trials and a number of activities enabling transition towards being a commercial organization, we are pleased to welcome Dr. Quigley, our second Gilead-designated Board Member, and Dr. Perlman, two advisors that will bring additional knowledge, wisdom and deep content expertise to our already-exceptional Board,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “All of our Board members bring unique, complementary and highly relevant perspectives, driven by diverse experiences from their own careers in biotechnology, and they unquestionably are an integral part of our team, working with Arcus to create extraordinary long-term value for patients and its shareholders.”

Dr. Perlman has been a long-time leader in the biotechnology field and has participated in the field’s evolution in a number of roles. After holding a faculty position at Stanford from 1984-1987, Dr. Perlman joined Genentech as Senior Director of Clinical Research, working there from 1988-1993 and contributing to their early success, including playing a key role in the development, FDA approval and marketing of the human growth hormone, Nutropin® (somatropin). He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s business development, investor relations and financing activities, culminating with Tularik’s acquisition by Amgen in 2004. Dr. Perlman’s experience also included serving as CEO of Affymax, and he is currently Managing Director and Head of non-clinical Development of X-37, LLC, an artificial intelligence-enabled drug discovery company, as well as the Chief Medical Officer and Managing Director of Velocity Pharmaceutical Development. Dr. Perlman earned his M.D. and Ph.D. degrees from New York University, and carried out post-doctoral research in the laboratory of Nobel Laureate Professor Eric Kandel. He completed his post-graduate clinical training at NYU and Stanford School of Medicine.

Dr. Quigley has spent his entire career focused on oncology drug discovery, both on the preclinical and translational fronts of the field. He is currently the Senior Vice President of Research Biology at Gilead Sciences, overseeing the company’s biology teams and preclinical programs as well as protein biotherapeutics and computational biology and bioinformatics efforts across all therapeutic areas. Prior to that, he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center at Bristol-Myers Squibb and site head of the company’s Redwood City, California location. In that role, Dr. Quigley was responsible for setting strategy for Bristol-Myers Squibb’s oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies, with focus on developing new therapies at the intersection of tumor, stromal and immune biology within the tumor microenvironment to enhance responsiveness to checkpoint blockade and other targeted therapies. Dr. Quigley previously worked in oncology discovery at MedImmune and Janssen. Dr. Quigley earned his Ph.D. degree in Immunology from Duke University and conducted post-doctoral research at the Dana Farber Cancer Institute, Department of Pediatric Oncology. He serves on the Scientific Advisory Board of the Keystone Symposia as well as Enara Bio and on the Board of Directors for Pionyr Immunotherapeutics.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab and AB154 plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, Arcus’s expectations for 2021 and its future as set forth in Dr. Rosen’s quote, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: the inherent uncertainty associated with the COVID-19 pandemic, including the duration and/or severity of the outbreak and actions by government authorities to contain or slow the spread of the virus; our dependence on our collaboration with Gilead for the successful development and commercialization of our investigational products; the inherent uncertainty associated with pharmaceutical product development and clinical trials; delays in our clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; the emergence of adverse events or other undesirable side effects; risks associated with preliminary and interim data; and changes in the competitive landscape for our programs. Risks and uncertainties facing Arcus are described more fully in Arcus’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 filed on November 5, 2020 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

The Arcus name and logo are trademarks of Arcus. All other trademarks belong to their respective owners.

Source: Arcus Biosciences

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event

Lille, France; Cambridge, MA; January 6, 2021GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at the following upcoming investor conferences and host a Primary Biliary Cholangitis (PBC) KOL event for the financial community.

Investor Conferences

  • Oddo 24th BHF Forum, January 7 – 8, 2021;
  • Solebury Trout Management Access Event, January 6 – 15, 2021;
  • Invest Securities Biomed Event, January 26 – 27, 2021;
  • Leerink Annual Global Healthcare Conference, February 23 – 25, 2021.

PBC KOL EVENT for the financial community

GENFIT will host a KOL event on Primary Biliary Cholangitis (PBC), the main indication for its lead product elafibranor, a dual PPAR a/d agonist. The event will feature presentations from GENFIT senior management and KOLs engaged in the management of PBC patients. The program will focus on the PBC treatment landscape, the utilization of elafibranor in PBC, and the PBC commercial opportunity. Two sessions will be organized, one in English and one in French. The event dates will be communicated shortly, and information will be available on the investor page of GENFIT’s corporate website, under the events section, at https://ir.genfit.com.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH.  NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | [email protected]

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | [email protected]

  GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com       

Attachment



TechTarget to Announce 2020 Fourth Quarter and Full Year Financial Results on February 10, 2021

TechTarget to Announce 2020 Fourth Quarter and Full Year Financial Results on February 10, 2021

Live Conference Call and Webcast Scheduled to Begin at 5:00 p.m. ET  

NEWTON, Mass.–(BUSINESS WIRE)–
Purchase intent-driven marketing and sales services company TechTarget, Inc. (Nasdaq: TTGT) today announced that it plans to release its 2020 fourth quarter and full year financial results after the market closes on Wednesday, February 10, 2021. The Company’s management team will host a live conference call and webcast at 5:00 p.m. Eastern Time on that day to discuss the Company’s financial results. In conjunction with the announcement and the call, the Company will distribute an update on the business, current market conditions, operational, and financial results for the applicable period, and other matters, with the call being reserved for a summary of financial highlights by management and Q&A. The financial results and a letter to shareholders will be accessible prior to the conference call and webcast on the investor information section of the Company’s website at https://investor.techtarget.com.

Conference Call Dial-In Information:

  • US callers: 1-888-339-0724
  • International callers: 1-412-902-4191
  • Canadian callers: 1-855-669-9657
  • Please access the call at least 10 minutes prior to the time the conference is set to begin.
  • Please ask to be joined into the TechTarget call.

Conference Call Webcast Information:

This webcast can be accessed at TechTarget’s website at http://investor.techtarget.com.

Conference Call Replay Information:

A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through March 10, 2021 at 9:00 a.m. ET.

For US callers to hear the replay, dial 1-877-344-7529 and use the conference number 10150901.

International callers dial 1-412-317-0088 and also use the conference number 10150901.

Canadian callers dial 1-855-669-9658 and also use the conference number 10150901.

A Web version will also be available for replay on http://investor.techtarget.com during the same period.

About TechTarget

TechTarget (Nasdaq: TTGT) is the global leader in purchase intent-driven marketing and sales services that deliver business impact for enterprise technology companies. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies’ information technology needs. By understanding these buyers’ content consumption behaviors, TechTarget creates the purchase intent insights that fuel efficient and effective marketing and sales activities for clients around the world.

TechTarget has offices in Boston, London, Munich, Paris, San Francisco, Singapore and Sydney. For more information, visit techtarget.com and follow us on Twitter @TechTarget.

(C) 2021 TechTarget, Inc. All rights reserved. TechTarget and the TechTarget logo are registered trademarks of TechTarget. All other trademarks are the property of their respective owners.

Investor Inquiries

Daniel Noreck

Chief Financial Officer

TechTarget, Inc.

617-431-9449

[email protected]

Media Inquiries

Garrett Mann

Director of Marketing

TechTarget, Inc.

617-431-9371

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Other Communications Internet Publishing Marketing Advertising Communications Technology Other Technology

MEDIA:

Logo
Logo

AerCap Holdings N.V. Announces Pricing of $1 Billion Aggregate Principal Amount of Senior Notes

PR Newswire

DUBLIN, Jan. 6, 2021 /PRNewswire/ — AerCap Holdings N.V. (“AerCap” or the “Company”) (NYSE: AER) has announced today that AerCap Ireland Capital Designated Activity Company and AerCap Global Aviation Trust (together, the “Issuers”), each a wholly-owned subsidiary of the Company, priced their offering of senior notes, consisting of $1,000,000,000 aggregate principal amount of 1.75% Senior Notes due 2026 (the “Notes”). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain other subsidiaries of the Company. The Issuers intend to use the net proceeds from the Notes for general corporate purposes.

Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, SG Americas Securities, LLC, TD Securities (USA) LLC and Truist Securities, Inc. are serving as joint book running managers for the underwritten public offering.

The Company has filed a registration statement (including a prospectus) on Form F-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the underwritten offering to which this communication relates. The registration statement automatically became effective upon filing on April 6, 2018. Investors should read the accompanying prospectus dated April 6, 2018, the preliminary prospectus supplement relating to the offering dated January 6, 2021 and other documents the Company has filed with the SEC for more complete information about the Company and this offering. These documents may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov.

The prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by e-mail at [email protected] or by calling toll-free at 1-800-831-9146; Morgan Stanley & Co. LLC, 180 Varick Street, New York, New York 10014, Attention: Prospectus Department or by e-mail at [email protected]; SG Americas Securities, LLC, 245 Park Avenue, New York, New York 10167, Attention: Transaction Execution Group, or by calling toll-free at 1-855-881-2108; TD Securities (USA) LLC, 31 W. 52nd Street – 2nd Floor, New York, New York 10019, Attention: Syndicate Department, or by calling toll-free at 1-855-495-9846; or Truist Securities, Inc., 303 Peachtree Street, Atlanta, Georgia 30308, Attention: Prospectus Department, or by calling toll-free at 1-800-685-4786.

This press release shall not constitute an offer to sell or purchase or the solicitation of an offer to sell or purchase the Notes or any other securities, nor shall there be any offer, solicitation, purchase or sale of these securities in any state or jurisdiction in which such offer, solicitation, purchase or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AerCap

AerCap is the global leader in aircraft leasing with one of the most attractive order books in the industry. AerCap serves approximately 200 customers in approximately 80 countries with comprehensive fleet solutions. AerCap is listed on the New York Stock Exchange (AER) and has its headquarters in Dublin with offices in Shannon, Los Angeles, Singapore, Amsterdam, Shanghai, Abu Dhabi, Seattle and Toulouse.

Forward-Looking Statements

This press release contains certain statements, estimates and forecasts with respect to future performance and events. These statements, estimates and forecasts are “forward-looking statements”. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “may,” “might,” “should,” “expect,” “plan,” “intend,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue” or the negatives thereof or variations thereon or similar terminology. All statements other than statements of historical fact included in this press release are forward-looking statements and are based on various underlying assumptions and expectations and are subject to known and unknown risks, uncertainties and assumptions, and may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors, including the impacts of, and associated responses to, the Covid-19 pandemic, that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied in the forward-looking statements. As a result, we cannot assure you that the forward-looking statements included in this press release will prove to be accurate or correct. In light of these risks, uncertainties and assumptions, the future performance or events described in the forward-looking statements in this press release might not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aercap-holdings-nv-announces-pricing-of-1-billion-aggregate-principal-amount-of-senior-notes-301202298.html

SOURCE AerCap Holdings N.V.

Quanterix Corporation to Present At 39th Annual J.P. Morgan Healthcare Conference

Quanterix Corporation to Present At 39th Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company’s growth and vision for the fifth consecutive year at the 39th Annual J.P. Morgan Healthcare Conference, taking place virtually. Hrusovsky’s session will take place on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST (12:40 p.m., PST) and will be made available to attendees and public listeners here.

Webcast Information

To access the live webcast of Quanterix’ presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST, please visit: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35235-quanterix-corporation/webcast?gpu_only=true&kiosk=true.

Replays of the webcasts will be available for a limited period following the conference.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Media Contact:

PAN Communications

Staci Didner, (407) 734-7325

[email protected]

Investor Relations Contact:

Stephen Hrusovsky

(774) 278-0496

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Cardiology Biotechnology Technology Other Health Health Oncology Other Science Other Technology Research Infectious Diseases Science

MEDIA:

Logo
Logo

Medical Properties Trust Announces Public Offering of 32,000,000 Shares of Common Stock

Medical Properties Trust Announces Public Offering of 32,000,000 Shares of Common Stock

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Medical Properties Trust, Inc. (the “Company”) (NYSE: MPW) announced today that it has commenced an underwritten public offering to sell 32,000,000 shares of its common stock. The Company intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 4,800,000 shares of its common stock.

The Company intends to use the net proceeds from the offering to fund in part the previously announced transactions related to the acquisition of a portfolio of behavioral healthcare real estate assets located throughout the United Kingdom currently owned and operated by the Priory Group (“Priory”), a leading private provider of behavioral care in the United Kingdom, as well as the related costs and expenses of the transactions. The offering is not conditioned upon the successful completion of the Priory acquisition. The Company intends to use any remaining balance of the net proceeds from the offering (or if the Priory acquisition is not completed) for general corporate purposes, which may include repaying indebtedness (including amounts outstanding from time to time under its revolving credit facility and/or term loan facilities), working capital and capital expenditures, and potential future acquisitions.

Goldman Sachs & Co., LLC, BofA Securities, and J.P. Morgan will act as joint book running managers for the offering. The offering will be made under the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”). When available, a copy of the preliminary prospectus supplement, final prospectus supplement and the prospectus relating to the offering may be obtained from Goldman Sachs & Co., LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, by phone at 866-471-2526 or by email at [email protected], BofA Securities, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at [email protected], and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204 or by email at [email protected], or by visiting the EDGAR database on the SEC’s web site at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any shares of the Company’s common stock, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed to acquire and develop net-leased hospital facilities. The Company’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

This press release includes “forward-looking statements” within the meaning of securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding the Company’s plans, strategies, objectives, targets, future expansion and development activities and expected financial performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward‐looking statements, including without limitation: the satisfaction of all conditions to, and the timely closing (if at all), of the Priory acquisition and related transactions; the risk that this offering may not be completed on the proposed terms, if at all; the ability of the Company’s tenants to meet the terms of their agreements; expected payout ratio; the amount of acquisitions of healthcare real estate, if any; capital markets conditions; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in certain hospital operations and the timing of such income; the payment of future dividends, if any; completion of additional debt or equity arrangements, and additional investments; national and international economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular; and the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis, and the factors referenced under the section captioned “Item 1.A Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2019 and our Form 10-Q for the quarter ended March 31, 2020. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and the Company disclaims any responsibility to update such information.

Drew Babin, CFA

Senior Managing Director – Corporate Communications

Medical Properties Trust, Inc.

(646) 884-9809

[email protected]

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Hospitals Construction & Property Health REIT

MEDIA:

Logo
Logo

T-Mobile Adds 5.5 Million Postpaid Customers in 2020 – the Most in Company History – and Further Expands 5G Network Leadership by Exceeding Ambitious 2020 5G Goals

T-Mobile Adds 5.5 Million Postpaid Customers in 2020 – the Most in Company History – and Further Expands 5G Network Leadership by Exceeding Ambitious 2020 5G Goals

America’s Largest 5G Network Now Brings Ultra Capacity 5G’s Game-Changing Speeds to 106 Million People and Reaches 280 Million People Nationwide

Preliminary Fourth Quarter 2020 Customer Results Expected to Lead the Industry Again

  • 1.7 million total net additions
  • 1.6 million postpaid net additions
  • 824,000 postpaid phone net additions

Preliminary Full-Year 2020 Customer Results Highlighted by Record-High Postpaid Net Additions

  • 5.6 million total net additions
  • 5.5 million postpaid net additions
  • 2.2 million postpaid phone net additions

Expanding 5G Network Leadership

  • Extended Range 5G covers 280 million people across nearly 1.6 million square miles, nearly 4x more than Verizon and over 2.5x more than AT&T
  • Ultra Capacity 5G covers 106 million people, over 50x more than Verizon’s 5G Ultra Wideband, with nationwide coverage expected by the end of 2021

BELLEVUE, Wash.–(BUSINESS WIRE)–
T-Mobile US, Inc. (NASDAQ: TMUS) provided a preliminary view of key customer results for the fourth quarter and full-year 2020, including its highest postpaid net additions in company history at 5.5 million for the full-year 2020. In the fourth quarter, T-Mobile is expected to lead the industry again across several key metrics with 1.7 million total net additions, 1.6 million postpaid net additions, and 824,000 postpaid phone net additions.

T-Mobile further expanded its 5G network leadership, now reaching 280 million people and covering 106 million people with Ultra Capacity 5G’s super-fast speeds enabled by mid-band (2.5 GHz) and millimeter wave spectrum. The 106 million surpassed the company’s aggressive goal to cover 100 million Americans by the end of 2020 and compared to an estimated 2 million people covered by Verizon’s Ultra Wideband 5G, showcasing T-Mobile’s dramatic lead in the 5G race.

“Our focus on bringing unmatched value and experience to customers while building and delivering the nation’s best 5G network paid off with record-breaking results in 2020 (5.5 million new postpaid customers!) – and we continue to be the growth leader in wireless,” said Mike Sievert, T-Mobile CEO. “Our 5G leadership position is getting stronger every day. We set some huge goals in 2020 that some thought were impossible, but we smashed them. Today, T-Mobile’s high speed Ultra Capacity 5G covers over 50 times more people than Verizon and it’s growing. We continue to demonstrate that we are way ahead of the competition on 5G and poised to become the country’s overall network leader. The network performance we’re delivering right here, right now, is setting the stage for what’s next. This is what leadership looks like!”

Preliminary Fourth Quarter and Full-Year 2020 Customer Results

  • Total net customer additions were 1.7 million in Q4 2020 and 5.6 million for the full-year 2020, the highest annual number in four years. The total customer count increased to a record-high of 102.1 million.
  • Postpaid net customer additions were 1.6 million in Q4 2020 and 5.5 million for the full-year 2020, the highest annual number in company history.
  • Postpaid phone net customer additions were 824,000 in Q4 2020 and 2.2 million for the full-year 2020. Postpaid phone churn was 1.03% in Q4 2020 and 0.90% for the full-year 2020.
  • Postpaid other net customer additions were 794,000 in Q4 2020 and 3.3 million for the full-year 2020, the highest annual number in company history.
  • Prepaid net customer additions were 84,000 in Q4 2020 and 145,000 for the full-year 2020. Prepaid churn was 2.92% in Q4 2020 and 3.03% for the full-year 2020.

Customer results for the fourth quarter and full-year 2020 are preliminary and subject to change pending completion of year-end closing review procedures. On April 1, 2020, T-Mobile completed its merger with Sprint. The following table reflects the combined company results of T-Mobile subsequent to the merger date for Q2 2020 through Q4 2020, while prior periods represent the historical results of standalone T-Mobile.

 

Quarter

 

Year

(in thousands, except churn)

Q4 2020

 

Q3 2020

 

Q4 2019

 

2020

 

2019

Net customer additions

1,702

 

 

2,035

 

 

1,391

 

 

5,631

 

 

4,854

 

Postpaid net customer additions

1,618

 

 

1,979

 

 

1,314

 

 

5,486

 

 

4,515

 

Postpaid phone net customer additions

824

 

 

689

 

 

1,001

 

 

2,218

 

 

3,121

 

Postpaid other net customer additions

794

 

 

1,290

 

 

313

 

 

3,268

 

 

1,394

 

Prepaid net customer additions

84

 

 

56

 

 

77

 

 

145

 

 

339

 

Total customers, end of period (1)

102,064

 

 

100,362

 

 

67,894

 

 

102,064

 

 

67,894

 

Postpaid phone churn

1.03

%

 

0.90

%

 

1.01

%

 

0.90

%

 

0.89

%

Prepaid churn

2.92

%

 

2.86

%

 

3.97

%

 

3.03

%

 

3.82

%

  1. In Q2 2020 T-Mobile acquired the customers of Sprint and made certain adjustments to align the customer reporting policies of T-Mobile and Sprint, resulting in the acquisition of 29,228,000 additional customers, net of base adjustments. Please reference the T-Mobile Quarterly Report for the quarterly period ended June 30, 2020, for a detailed reconciliation of the acquired customers and base adjustments.

Expanding 5G Network Leadership

T-Mobile is America’s 5G leader, delivering 5G speeds in more places with the first and largest nationwide 5G network. T-Mobile’s Extended Range 5G covers 280 million people across nearly 1.6 million square miles – offering nearly 4x more geographic coverage than Verizon and over 2.5x more than AT&T.

T-Mobile’s Ultra Capacity 5G, which is enabled by mid-band (2.5 GHz) and millimeter wave spectrum, has been rapidly expanding and now covers 106 million people, over 50x more than Verizon’s 5G Ultra Wideband. Ultra Capacity 5G is available in more than 1,000 cities and towns across the country including major markets such as Chicago, Houston, Los Angeles, New York City, Philadelphia, and Washington D.C. The performance of Ultra Capacity 5G is incredible, delivering download speeds in the 300 Mbps range and peak speeds hitting one Gbps on compatible 5G devices.

The company expects its Ultra Capacity 5G service to reach nationwide coverage by the end of 2021.

Contact Information

T-Mobile Social Media

Investors and others should note that we announce material financial and operational information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. We also intend to use certain social media accounts as means of disclosing information about us and our services and for complying with our disclosure obligations under Regulation FD (the @TMobileIR Twitter account (https://twitter.com/TMobileIR) and the @MikeSievert Twitter (https://twitter.com/MikeSievert) account, which Mr. Sievert also uses as a means for personal communications and observations). The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following our press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described above may be updated from time to time as listed on our investor relations website.

About T-Mobile US, Inc.

T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: http://www.t-mobile.com.

Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including information concerning T-Mobile US, Inc.’s future results of operations, are forward-looking statements. These forward-looking statements are generally identified by the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “could” or similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties and may cause actual results to differ materially from the forward-looking statements. Important factors that could affect future results and cause those results to differ materially from those expressed in the forward-looking statements include, among others, the following: the failure to realize the expected benefits and synergies of the merger with Sprint Corporation (“Sprint”), pursuant to the Business Combination Agreement with Sprint and the other parties named therein (as amended, the “Business Combination Agreement”), and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”) in the expected timeframes, in part or at all; adverse economic, political or market conditions in the U.S. and international markets, including those caused by the coronavirus disease 2019 (“COVID-19”) pandemic, and the impact that any of the foregoing may have on us and our customers and other stakeholders; costs of or difficulties in integrating Sprint’s network and operations into our network and operations, including intellectual property and communications systems, administrative and information technology infrastructure and accounting, financial reporting and internal control systems; changes in key customers, suppliers, employees or other business relationships as a result of the consummation of the Transactions; the risk that our business, investor confidence in our financial results and stock price may be adversely affected if our internal controls are not effective; the risk of future material weaknesses resulting from the differences between T-Mobile’s and Sprint’s internal controls environments as we work to integrate and align policies and practices; the impacts of the actions we have taken and conditions we have agreed to in connection with the regulatory proceedings and approvals of the Transactions including the acquisition of Sprint’s prepaid wireless business by DISH Network Corporation (“DISH”) (excluding the Assurance brand Lifeline customers and the prepaid wireless customers of Shenandoah Telecommunications Company and Swiftel Communications, Inc.), including customer accounts, inventory, contracts, intellectual property and certain other specified assets (the “Prepaid Transaction”), the complaint and proposed final judgment agreed to by us, DT, Sprint, SoftBank and DISH with the U.S. District Court for the District of Columbia, which was approved by the Court on April 1, 2020, the proposed commitments filed with the Secretary of the FCC, which we announced on May 20, 2019, certain national security commitments and undertakings, and any other commitments or undertakings entered into, including but not limited to those we have made to certain states and nongovernmental organizations; the ongoing commercial and transition services arrangements that we entered into with DISH in connection with such Prepaid Transaction, which we completed on July 1, 2020; the assumption of significant liabilities, including the liabilities of Sprint in connection with, and significant costs, including financing costs, related to the Transactions; our ability to make payments on debt or to repay existing or future indebtedness when due or to comply with the covenants contained therein; adverse changes in the ratings of our debt securities or adverse conditions in the credit markets; natural disasters, public health crises, including the COVID-19 pandemic, terrorist attacks or similar incidents; competition, industry consolidation and changes in the market for wireless services, which could negatively affect our ability to attract and retain customers; the effects of any future merger, investment, or acquisition involving us, as well as the effects of mergers, investments or acquisitions in the technology, media and telecommunications industry; breaches of our and/or our third-party vendors’ networks, information technology and data security, resulting in unauthorized access to customer confidential information; the inability to implement and maintain effective cybersecurity measures over critical business systems; challenges in implementing our business strategies or funding our operations, including payment for additional spectrum or network upgrades; the impact on our networks and business from major system and network failures; difficulties in managing growth in wireless data services, including network quality; material changes in available technology and the effects of such changes, including product substitutions and deployment costs and performance; the timing, scope and financial impact of our deployment of advanced network and business technologies; the occurrence of high fraud rates related to device financing, customer credit cards, dealers, subscriptions or account take over fraud; our inability to retain and hire key personnel; any changes in the regulatory environments in which we operate, including any increase in restrictions on the ability to operate our networks and changes in data privacy laws; unfavorable outcomes of existing or future litigation or regulatory actions, including litigation or regulatory actions related to the Transactions; the possibility that we may be unable to adequately protect our intellectual property rights or be accused of infringing the intellectual property rights of others; changes in tax laws, regulations and existing standards and the resolution of disputes with any taxing jurisdictions; the possibility that we may be unable to renew our spectrum leases on attractive terms or acquire new spectrum licenses or leases at reasonable costs and terms; any disruption or failure of third parties (including key suppliers) to provide products or services; material adverse changes in labor matters, including labor campaigns, negotiations or additional organizing activity, and any resulting financial, operational and/or reputational impact; changes in accounting assumptions that regulatory agencies, including the U.S. Securities and Exchange Commission, may require, which could result in an impact on earnings; and interests of our significant stockholders that may differ from the interests of other stockholders. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law.

T-Mobile US Media Relations

[email protected]

or

Investor Relations

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Networks Consumer Electronics Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo